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Abstract
GOALS—To determine the role of NSAIDs in activation of IBD.
BACKGROUND—Non-steroidal anti-inflammatory drugs (NSAIDs) may activate inflammatory 
pathways in inflammatory bowel disease (IBD).
STUDY—Crohn’s and Colitis Foundation of American (CCFA) Partners is an ongoing cohort 
study of patients living with IBD. All data are self-reported via the internet. We identified a sub-
cohort of participants whose disease activity, based on short Crohn’s Disease Activity Index 
(sCDAI) and simple clinical colitis activity index (SCCAI), indicated remission. Pattern of use of 
NSAIDs was measured at baseline, and disease activity assessment was performed 6 months later. 
We used multivariate binomial regression to determine effects of NSAIDs on disease activity.
RESULTS—A total of 791 individuals in remission had baseline and follow data available for 
analysis. Of these, 247 Crohn’s disease (CD) patients (43.2%) and 89 ulcerative colitis (UC) 
patients (40.6%) reported NSAID use. CD patients with NSAID use ≥ 5 times/monthly had greater 
risk of active disease at follow-up (23% v. 15%, p=0.04); (adjusted risk ratio (RR) 1.65; 95% 
confidence interval (CI) 1.12–2.44). No effect was observed in patients with UC (22% vs 21%, 
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p=0.98; adjusted RR 1.25; 95% CI, 0.81–1.92). Acetaminophen use was associated with active 
disease at follow-up in CD (adjusted RR 1.72, 95% CI 1.11–2.68).
CONCLUSIONS—Regular (≥ 5 times/monthly) NSAID and acetaminophen use were associated 
with active CD, but not UC. Less frequent NSAID use was not associated with active CD or UC. 
These findings indicate that regular NSAID use may increase CD activity, or that NSAID use may 
be a marker of a less robust remission; thus reflecting subclinical disease activity.
Introduction
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis 
(UC) are chronic relapsing inflammatory disorders of the gastrointestinal tract of unknown 
etiology. These diseases are thought to arise via a combination of genetic, environmental 
and microbial (microbiota) effects.1,2 Unfortunately, causative agents of relapses of 
inflammation in these disorders are not well characterized. Etiologies of disease relapse are 
a high priority for research.3
Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of pain medications that have 
been associated with increased risk of IBD development.4 NSAIDs are also known to cause 
enteropathy and gastropathy, which could contribute to or trigger disease exacerbation. The 
proposed mechanisms associated with these effects include decreased production of 
prostaglandins (through both cyclooxygenase (COX) 1 and COX-2 pathways) and topical 
actions via surface membrane phospholipid interaction and effects on mitochondrial 
activity.5,6 It is possible that these medications play a role in activation of inflammatory 
pathways in IBD through similar mechanisms.
Prior data on NSAID use and relapse of IBD are conflicting. Data in the form of case-
series,7,8 a case control study with hospitalization for IBD as the outcome,9 and one small 
trial6 demonstrated a detrimental effect of NSAID use in individuals with IBD. The trial 
demonstrated a 17–28% relapse rate within 9 days of ingestion. Other studies, including 
cross-sectional10 and cohort studies11,12 found no effect of NSAIDs on disease activity.
Patients with IBD may have a number of extra-intestinal conditions including painful axial 
and peripheral arthopathy. Even though the literature on IBD exacerbation from NSAIDs is 
limited, patients are often instructed by their physicians to avoid these inexpensive and 
possibly helpful medications. In order to learn more about the association between NSAIDS 
and IBD exacerbation we examined data from a large IBD cohort study. We aimed to 
determine whether NSAID use increases the risk of increased disease activity in a 
population of patients with IBD in remission.
Materials and Methods
Crohn’s and Colitis Foundation of American (CCFA) Partners is an ongoing cohort study of 
patients living with IBD. All data are self-reported via the internet.13 Following a baseline 
survey, participants complete online surveys every 6 months. Data on demographics, disease 
type and characteristics, medications, disease activity (via the short Crohn’s disease activity 
index (sCDAI) for CD and the simple clinical colitis activity index (SCCAI) for UC as well 
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as the Manitoba Index) and other patient reported outcomes are collected at each interval. 
We performed a cohort study nested within CCFA Partners. For inclusion, individuals had to 
1) have IBD, 2) be in remission at baseline (defined as sCDAI <150 or SCCAI ≤2) 3) 
provide complete NSAID and non-NSAID pain medication histories at baseline and 4) not 
change diagnoses (CD or UC) during the study. A similar design has been used in another 
study within this cohort of factors associated with relapse of IBD.14
The main exposure was NSAID use. Data were collected on current use of NSAIDs and 
average number of doses per month. Similar data were collected for non-NSAID pain 
medications (acetaminophen). Exposure definitions were determined a priori, and included 
categories of any/none and ≥5 times/monthly versus <5 times/monthly. The cutoff of 5 times 
monthly was felt to represent “regular” use, due to an average of greater than once weekly 
use. The main outcome of interest was active disease at 6 months of follow-up, defined by 
sCDAI ≥ 150 and SCCAI >2. Alternate outcomes were investigated in sensitivity analyses, 
including sCDAI >250 and SCCAI >4 and the Manitoba index for IBD.
Bivariate analyses were used to calculate associations between exposures and outcome. 
Binomial regression models were used to control for potential confounders and to determine 
the independent effects of NSAIDs on active disease at follow-up. All statistical analyses 
were performed using Stata version 11.0 (College Station, TX, USA). For all analyses, p-
values were two-sided, and a p-value of 0.05 or less was considered statistically significant. 
The study protocol was approved by the Institutional Review Board at the University of 
North Carolina.
Results
A total of 1617 individuals with IBD met inclusion criteria for the study. Of these, 791 
(49%) completed a follow-up survey. When comparing the 826 on whom no follow-up 
information was available to those who did complete follow-up, there was no substantial 
difference between NSAID use or other baseline characteristics between the groups. The 
entire population met criteria for remission at baseline, with a median cCDAI of 93 (cut off 
for remission <150) for CD patients and mean SCCAI of 1.1 (cut off for remission of ≤2) for 
UC patients. There was no significant difference in sCDAI or SCCAI at baseline when 
stratified by any NSAID use. A total of 572 individuals (72.3%) had CD and 219 (27.7%) 
had UC. Of these, 336 (42.5%) reported any use of NSAIDs at baseline, with similar rates of 
any NSAID usage for both CD and UC patients (43.2% and 40.7%, respectively). Overall, 
NSAID uses/month ranged from 1–180 times per month. The median NSAID uses/month 
was 4.3 (IQR 2–13). The characteristics of the population by any NSAID use are shown in 
table 1. In general, the 2 groups were similar without specific factors associated with 
NSAID exposure.
When evaluating categories of pain medication use, very few (3.8%) used prescription 
NSAIDs (selective COX-2 inhibitors, diclofenac, indomethacin, meloxicam, etc), 19.3% 
reported ≥5 uses/month (“regular” use) of NSAIDs, and nearly 2/3 reported acetaminophen 
use (64.6%) (figure 1). On bivariate analysis, for the IBD population overall, there was no 
significant difference between any versus no NSAID use or ≥5 times monthly versus <5 
Long et al. Page 3









times monthly NSAID use and active disease at follow up (19% v. 17%, p=0.54 and 23% v. 
17%, p=0.09, respectively). However, when stratified by CD or UC, there was a significant 
difference in disease activity at follow-up among those with CD reporting ≥5 uses/month of 
NSAIDS, (23% v. 15%, p=0.04). Interestingly, there was also an increased risk of active 
disease at follow-up for CD patients reporting acetaminophen use at baseline (20% v. 11%, 
p=0.01). For patients with UC, there was no difference in active disease at follow up for any 
NSAID use versus none (24% vs 20%, p=0.52) or for ≥5 times/monthly NSAID use versus 
<5 times/monthly (22% vs 21%, p=0.98) (figure 2). Unadjusted risk ratios for active disease 
at follow-up, stratified by disease type, are shown in table 2.
In binomial regression models controlling for IBD medication use, smoking, sex, age and 
other NSAID or acetaminophen use, individuals with CD with ≥5 uses/month of NSAIDS 
had significantly increased risk of active disease at follow-up (adjusted risk ratio (RR) of 
1.65; 95% confidence interval (CI) 1.12–2.44.) Acetaminophen use at baseline among 
individuals with CD was also independently associated with active disease at follow-up 
(adjusted RR 1.72; 95% CI 1.11–2.68). No independent association was found between 
regular use (≥ 5 uses/month) of NSAIDs at baseline and active disease at follow up for UC 
(adjusted RR 1.25; 95% CI 0.82–1.92). Acetaminophen use at baseline also was not 
associated with active disease at follow up for UC (adjusted RR 1.09; 95% CI 0.75–1.57).
In sensitivity analyses evaluating alternate outcomes, similar trends were seen in the IBD 
population as a whole using the Manitoba index as the outcome (increased activity defined 
as sometimes, often or constant activity at follow-up). When we evaluated only the CD 
population for this outcome, 23.2% with ≥5 uses NSAIDs/month had active disease at 
follow up, compared to 18.9% with <5 uses NSAIDs/month (p=0.23). Using the outcome of 
sCDAI >250 for active disease, similar trends were again seen with more active disease 
among those with “regular” use, although none reached statistical significance. Using this 
definition requiring a higher level of active disease in CD, 6.9% of those with NSAID use 
≥5 times monthly had active disease, as compared to 4.0% of those with NSAID use <5 
times/monthly (p=0.17).
Discussion
In this study of NSAID and acetaminophen use at baseline and active disease in patients 
with IBD, we observed several important findings. First, use of NSAIDs among patients 
with IBD is common, despite the fact that many gastroenterologists caution against NSAID 
use in IBD patients. We also found that low doses of NSAIDS in patients with CD, or any 
NSAID use in those with UC, do not appear to impact disease activity. However, higher or 
“regular” NSAID doses (≥5 times monthly) are associated with active disease at follow-up 
among patients with CD in our study.
The prevalence of NSAID use in this internet-based cohort of predominantly individuals in 
the United States was similar to that previously reported in a population-based cohort from 
Canada.12 The literature has been conflicting as to the effects of NSAIDs, but this may be 
partially explained by a possible dose-response effect with NSAIDs and small numbers in 
prior studies, particularly for subgroup analyses. Because of the large size of our study and 
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our detailed information about NSAIDs we were able to identify differing effects with a 
higher dose (using a threshold of ≥5 times/monthly). Study designs have also differed, with 
varying definitions of active disease or using proxy outcomes, such as hospitalization. The 
timing of NSAID use is also important, in that measurement of NSAID exposure at the time 
of a flare could be a consequence of the flare (due to abdominal or joint pain from 
inflammation) rather than a cause of the flare. For example, in a case-control study 
comparing those with UC admitted to the hospital, as compared to community controls, 
more individuals admitted to the hospital had recent or current NSAID use (OR 1.7–1.9).9 
However, NSAID use was measured in close proximity to the flare. In our study, we 
established use patterns at baseline while the individual was in remission, which allows us to 
separate NSAID use patterns from management of symptoms of a flare. Felder et at 
previously reported an association between NSAID use and IBD activity.15 Bernstein et 
al 12 demonstrated no increased risk of flare associated with NSAID use in a prospective 
IBD cohort in Manitoba. There was no evidence of a dose-response effect of NSAIDs. 
However, the population was not stratified by UC and CD to determine if there were 
disease-specific differences in flares by NSAID use. Bonner et al11 found no increase in 
disease activity associated with low dose NSAID use in CD or UC populations, similar to 
our findings. High dose NSAIDs were associated with higher numerical disease activity 
scores in CD patients, particularly for those with colonic involvement.11 These data and our 
data support a possible dose-response effect in those with CD.
There are several strengths of this study. First, the prospective design minimized the 
possibility of reverse causation, i.e. that NSAID exposure was impacted by the presence of 
active disease. This is important, as flares of disease can be accompanied by abdominal and 
joint pain, for which NSAIDs may be used. Additionally, the large sample size allowed us to 
separately analyze associations in patients with CD and UC, as is appropriate for 
biologically distinct conditions. Finally, we used validated indices for self-reported 
measurement of disease activity.16,17
There are also limitations to this study. First, our cohort is a self-reported cohort of 
individuals with IBD, and hence disease type is subject to misclassification. However, a 
recent validation study within CCFA Partners that found >95% accuracy of self-reported 
IBD diagnosis when compared to physician report.18 Also, there was substantial loss to 
follow-up within the cohort, which could have biased our results if this were differential. 
However, baseline characteristics and exposure status between those who did and who did 
not follow-up were not substantially different, suggesting that loss to follow-up was likely 
non-differential. We also did not have objective measures of inflammation, and factors such 
as endoscopic or laboratory evidence of inflammation were not available to confirm disease 
activity. Additionally, data were not available as to the indication for NSAID or 
acetaminophen use (headache, menorrhagia, abdominal pain, joint pain, etc) and NSAID 
exposure data were by self-report. We intentionally evaluated NSAID exposure patterns 
remote from a flare, in a population in remission, so as not to confound the association. 
Higher NSAID use immediately prior to a flare may be related to arthralgias or other pain 
directly related to the flare itself. However, it is possible that use patterns measured at 
baseline may not be consistent throughout the exposure window. A prior study by Bonner et 
al demonstrated an association with high dose NSAIDS and increased disease activity in 
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patients with colonic involvement of CD. Unfortunately, we were not able to stratify our 
analyses by disease location. Finally, this was a relatively short-term study with only 6 
months of follow-up. However, this time estimate is likely reasonable to study a short acting 
exposure such as pain medication use.
There are several implications to this study. First, the requirement for any pain medication 
while in remission may be a marker of occult disease. This occult disease may in fact be the 
risk factor for relapse, rather than the NSAID or acetaminophen. This is important to clinical 
care, as physicians should be suspicious that patients who appear to be in clinical remission 
yet require NSAIDS may have ongoing inflammation. For those with the requirement for 
regular use of these medications, further investigation may be warranted to determine if 
inflammation is present. It is also possible that a mechanism common to NSAIDS and 
acetaminophen may play a role in inflammation development in IBD. Importantly, we now 
also know that infrequent NSAID use does not increase disease activity for those in clinical 
remission with UC or CD, and can potentially be used intermittently without adverse 
consequences. Certainly, further prospective studies with objective inflammatory outcomes 
and mechanistic studies are needed to assess the risks of these pain medications during 
remission. Data gleaned from this study will enable providers to better counsel IBD patients 
on intermittent use of analgesics.
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Categories of pain medication use in cohort at baseline
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Categories of pain medication use at baseline and active disease at follow-up, stratified by 
Crohn’s disease or ulcerative colitis
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Table 1
Characteristics of the population in remission by non-steroidal anti-inflammatory drug (NSAID) use at 
baseline (n=791)
Characteristic Any NSAID use (n=336)
Mean (SD), median (IQR) or %
No NSAID use (n=455)
Mean (SD), median (IQR)or %
Age 43.8 (14.8) 44.8 (15.4)
IBD Type
 CD 73.5 71.4
 UC 36.5 28.6
Gender (% female) 71.1 67.3
Disease duration (years) 11 (6–22) 10 (4–20)
Smoking (% yes) 26.5 31.7
Medication use
 Steroids (% yes)* 10.1 11.4
 Immunomodulator** 24.4 25.3
 Anti-TNF^ 28.8 36.7
 5-ASA% 53.0 46.8
*including rectal preparations and budesonide
**
Thiopurine: azathioprine or mercaptopurine
^
anti-TNF: anti- tumor necrosis factor alpha agent
%5-aminosalicylate
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Table 2
Pain medication use at baseline and risk of symptoms of active inflammatory bowel disease at follow up
Medication Risk of active Crohn’s disease at follow up (n=572)
RR (95% CI)
Risk of active ulcerative colitis at follow up (n=219)
RR (95% CI)
Any NSAID** 1.05 (0.82–1.34) 1.13 (0.78–1.63)
NSAID ≥5 x/monthly 1.50 (1.04–2.18) 1.01 (0.49–2.06)
Any acetaminophen 1.21 (1.07–1.38) 1.06 (0.82–1.35)
*Unadjusted risk ratio and 95% confidence interval for active disease at follow up with use of drug as compared to no use
**Non-steroidal anti-inflammatory drug
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